In what would be a big boost for the national effort to end the menace of the COVID-19 pandemic, India is likely to have six different vaccines in the market by end of the year as per the details made public by Union Minister for Health Dr Harsh Vardhan, reports Times of India.
Dr Harsh Vardhan yesterday (6 March) shared that around 24 pharma companies are conducting trials for COVID-19 vaccines presently and that vaccines from six different companies would be available by the year-end.
Dr Harsh Vardhan also shared that India is already supplying vaccines to 60 nations across the globe. This gains significance as India is supplying vaccines to other nations while also inoculating its population.
Dr Harsh Vardhan shared the development while speaking at the inauguration of a COVID-19 diagnosis and research centre at the Indian Council of Medical Research (ICMR)'s National JALMA Institute for Leprosy and Other Mycobacterial Diseases in Agra.
India has authorised the use of Serum Institute of India (SII) manufactured Covishield and Bharat Biotech developed Covaxin vaccines.
It should be noted that Covishield has been developed by British-Swedish pharmaceutical giant AstraZeneca in collaboration with the University of Oxford. Meanwhile, Covaxin has been indigenously developed by Bharat Biotech in a close collaboration with ICMR and Pune based National Institute of Virology.
An Appeal...
Dear Reader,
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.